
Peptide T TFA
CAS No. 1610056-01-3
Peptide T TFA( —— )
Catalog No. M30571 CAS No. 1610056-01-3
Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 162 | Get Quote |
![]() ![]() |
10MG | 279 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePeptide T TFA
-
NoteResearch use only, not for human use.
-
Brief DescriptionPeptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
-
DescriptionPeptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.(In Vitro):Peptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4. Peptide T at 10-8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10-9 M concentration significantly inhibits IFN-g production by PBMC.(In Vivo):Peptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE.
-
In VitroPeptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4. Peptide T at 10-8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10-9 M concentration significantly inhibits IFN-g production by PBMC.
-
In VivoPeptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE.
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorCD4, HIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610056-01-3
-
Formula Weight971.89
-
Molecular FormulaC37H56F3N9O18
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2(8561):751.
molnova catalog



related products
-
BMS-986001
A thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-2 isolates from treatment-naive individuals with EC50 of 30-81 nM.
-
DMJ-I-228
A small molecule CD4-mimetic that binds gp120 and blocks CD4 binding, inhibits HIV-1 entry with IC50 of 86.9 uM.
-
(Rac)-Telinavir
(Rac)-Telinavir shows anti-HIV activity.